Rewards Outweigh Risk for Long-Term Equity Players: Featured Research on Pier 1 Imports, CarMax, Transocean, Enanta and Aratana

NEW YORK, December 22, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Pier 1 Imports (NYSE: PIR), CarMax (NYSE: KMX), Transocean (NYSE: RIG), Enanta (NASDAQ: ENTA), and Aratana (NASDAQ: PETX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

PIR Research Report: ( http://get.analystsreview.com/pdf/?c=Pier%201%20Imports&d=22-Dec-2014&s=PIR ),

KMX Research Report: ( http://get.analystsreview.com/pdf/?c=CarMax&d=22-Dec-2014&s=KMX ),

RIG Research Report: ( http://get.analystsreview.com/pdf/?c=Transocean&d=22-Dec-2014&s=RIG ),

ENTA Research Report: ( http://get.analystsreview.com/pdf/?c=Enanta&d=22-Dec-2014&s=ENTA ),

PETX Research Report: ( http://get.analystsreview.com/pdf/?c=Aratana&d=22-Dec-2014&s=PETX ).

============

--

Analyst Update: Financial Results, FDA Approvals, Study Results and Corporate Updates

Reviewed by: Rohit Tuli, CFA®  

The U.S. markets extended their gains for a third session on Friday with the S&P 500 adding up its second best week in almost two years. The Dow Jones Industrial Average finished at 17,804.80, up 0.15%, the NASDAQ Composite edged 0.36% higher at 4,765.38, and the S&P 500 advanced 0.46% to close the session at 2,070.65. The rally in the U.S. stocks was fueled by the Federal Reserve's assurance on Wednesday to take a patient approach towards raising interest rates, which calmed the investors over the policy outlook. On the other hand, the European markets ended Friday's session on a mixed note as Italian banking and healthcare stocks weighed down the wider benchmarks. The Asian markets extended the previous day's gain on Friday and ended on a positive note boosted by the momentum on Wall Street following the reassurance from Federal Reserve that interest rates would be hiked no sooner than mid-2015.

Pier 1 Imports Inc (Pier 1 Imports) reports Q3 FY 2015 earnings, in line with street expectations; Stock up over 9% in trade. The Company declared quarterly cash dividend of six cents to be paid on February 4, 2015 to shareholders of record on January 21, 2015. Read our research report on Pier 1 Imports to know about the latest results, analysts' estimate, and full-year outlook.

Shares of CarMax Inc. (CarMax) rallied after the Company reported better-than-expected Q3 FY 2015 financial results, helped by used-car sales. A total of 6.68 million shares changed hands, significantly higher than the 30-day average trading volume of 1.85 million. Read our research report on CarMax to more about the financial results, analyst estimates, and management's viewpoint.

Shares of Transocean Ltd (Transocean) up 7.86% in trade, after crude oil prices rebounded and the Company issued the monthly fleet update summary as per which it scrapped more rigs and said "additional rigs may be identified as candidates for scrapping." Read our research report on Transocean to know more about the Company and factors driving the prices of 'Black Gold' down.

Enanta Pharmaceuticals Inc (Enanta) gained 3.9% in trade to end at $46.62, amidst high trading volumes, after US FDA approval of AbbVie's VIEKIRA PAK. The biotechnology Company was recently added to the NASDAQ Biotechnology Index. Read about the drug approval and the Company financials, right here at Analysts Review.

Shares of Aratana Therapeutics Inc (Aratana) added almost 26% in trade to end at $16.43, amidst high trading volumes, after the Company announced positive top-line results from AT-001 pivotal field study in client-owned dogs with osteoarthritis. Read our report on Aratana to know more about the study results and management viewpoint on the same.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED